Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Dec 27;38(1):26–39. doi: 10.1161/ATVBAHA.117.305140

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 The Authors.

Arteriosclerosis, Thrombosis, and Vascular Biology is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

PMC Copyright notice

Figure 3. — Rosuvastatin treatment reduced CD41 immunostaining in coronary arteries of SR-B1^−/−/apoE^−/− mice. Indirect immunofluorescence staining (green) for CD41, a marker of activated platelets, is shown in A, D, F, and H; (C) no primary antibody control (nuclear DNA stained blue with DAPI). Oil red O/hematoxylin-stained adjacent sections are shown in B, D, F, and H. A and B, Partially and (D and E) completely occluded coronary arteries from control saline-treated SR-B1^−/−/apoE^−/− mice. F and G, Partially and (H and I) completely occluded coronary arteries from rosuvastatin-treated SR-B1^−/−/apoE^−/− mice. Scale bar=50 µm. J, The percentage of CD41-positive atherosclerotic coronary arteries and (K) the intensity of CD41 staining (normalized to plaque area) in positive coronary arteries from control saline- (n=13) and rosuvastatin-treated (n=14) SR-B1^−/−/apoE^−/− mice. L, Circulating platelet counts, (M) anti-P-selectin antibody binding, or (N) PE-JON/A (phycoerythrin-labeled JON/A; anti-GPIIbIIIa) antibody binding to platelets from control apoE^−/− (sKO) or control saline-treated or rosuvastatin-treated SR-B1^−/−/apoE^−/− (dKO) mice, detected by flow cytometry. Data in M and N are expressed as arbitrary fluorescence units. Data in J and K were analyzed by the Mann–Whitney rank sum test. Data in L through N were analyzed by 1-way ANOVA with the Kruskal–Wallis nonparametric test. *P=0.03, **P<0.01, *** P<0.002, and NS, not statistically significantly different vs control apoE^−/− (sKO) or control saline-treated SR-B1^−/−/apoE^−/− (dKO) mice. apoE indicates apolipoprotein E; C, control saline-treated SR-B1^−/−/apoE^−/− (dKO) mice; dKO, double knockout; R, rosuvastatin-treated SR-B1^−/−/apoE^−/− (dKO) mice; sKO, single knockout; and SR-B1, scavenger receptor class B type 1.